eXp Realty selects Cloze’s AI-powered real estate platform for CRM of Choice program Exclusive NFT Collectables ‘CBD All-Stars’ WIP Goes Live!
LONDON, UK / ACCESSWIRE / December 13, 2021 / The creators of Ethereum-based NFT token…
Love Hemp Group PLC Announces Full Year Results for the Year Ended 30 June 2021
LONDON, UK / ACCESSWIRE / December 13, 2021 / Love Hemp Group PLC (AQSE:LIFE) (OTCQB:WRHLF),…
NeoGenomics Appoints David Eberhard MD, PhD as Chief Medical Officer of Inivata Liquid Biopsy Subsidiary
FT MYERS, FL / ACCESSWIRE / December 13, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading…
Solid ETH States that Why They Should be Your Altcoin for the Next Bull Run!!
ÖSTERREICH, AUSTRIA / ACCESSWIRE / December 13, 2021 / SolidETH is this years paradigm shifting…
Westchester County Elder Law Attorney Anthony J. Enea Explores the Estate Implications of Divorce Later in Life
New ‘Talking Seniors’ podcast episode features matrimonial attorney John A. Pappalardo of Farber, Pappalardo &…
Great moment for Barca’s prodigy Pedri
Pedri wins the Golden Boy Award 2021 – and is already making arrangements for the…
Genmab Announces that Janssen has Received Conditional European Marketing Authorization for RYBREVANT® (amivantamab) for Patients with Advanced Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations, after Failure of Platinum-base
Media Release Copenhagen, Denmark, December 13, 2021 The European Commission has granted Janssen-Cilag International NV…
Novozymes and Saipem enter collaboration agreement to create a more sustainable CO2 capture
The partnership will develop new biotech solutions aimed at carbon capture through enzymes. COPENHAGEN, DENMARK…
OKYO Pharma Limited (“OKYO” or the “Company”) Announces First-in-Class Drug Candidate OK-101 Displaying Both Anti-inflammatory and Ocular Pain-Reducing Potential to Treat Dry Eye Disease
LONDON, Dec. 13, 2021 (GLOBE NEWSWIRE) — OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a…
Nicox Appoints Doug Hubatsch as new Chief Scientific Officer to lead Clinical and Non-clinical Development
Press Release Nicox Appoints Doug Hubatsch as new Chief Scientific Officer to lead Clinical and…
OSE Immunotherapeutics Presents First Preclinical Efficacy Data on Anti-IL-7 Receptor Antagonist OSE-127 in Acute Lymphoblastic Leukemia
At the 2021 American Society of Hematology (ASH) Annual Meeting NANTES, France, Dec. 13, 2021…
Roche launches the AVENIO Edge System to simplify and automate next-generation sequencing sample preparation, reduce human error and advance precision medicine
Next-generation sequencing (NGS) enables a better understanding of genetic mechanisms linked to specific diseases and…
Acacia Pharma Announces Successful Completion of BARHEMSYS® Post-approval Requirement Study in Patients with Severe Renal Impairment
This announcement contains inside information for the purposes of Article 7 of the Market Abuse…
Interim data from phase III HAVEN 6 study demonstrate favourable safety and efficacy profile of Roche’s Hemlibra in people with moderate or mild haemophilia A
People with moderate or mild haemophilia A have significant unmet clinical needs, as this population…
ObsEva Appoints Will Brown as Chief Financial Officer
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland…
Positive Phase 3 Dupixent® (dupilumab) data in children 6 months to 5 years with moderate-to-severe atopic dermatitis featured in RAD 2021 late-breaking session
Positive Phase 3 Dupixent® (dupilumab) data in children 6 months to 5 years with moderate-to-severe…
Idorsia to further characterize lucerastat for the treatment of Fabry disease by continuing the open-label extension of the Phase 3 MODIFY study
Ad hoc announcement pursuant to Art. 53 LR Idorsia to further characterize lucerastat for the…
Avenue Therapeutics Prices $2.0 Million Underwritten Public Offering of Common Stock
NEW YORK, Dec. 12, 2021 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a…
Editas Medicine Reports Preclinical Data Demonstrating Robust Tumor Reduction and Clearance Using Novel, Engineered iNK Cells at the American Society of Hematology Annual Meeting
Preclinical data demonstrating Editas-engineered AsCas12a multiplexed editing of iPSCs enhances iNK tumor killing ability, supporting…
NexImmune Announces Preliminary Phase 1/2 NEXI-002 Results in Patients with Multiple Myeloma
Initial Phase 1/2 data presented at the 63rd American Society of Hematology (ASH) Annual Meeting…